Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
clinical trials
life sciences
national blog main
europe blog main
brexit
drugs
europe
falsified medicines
innovation
labeling
mhra
national
regulations
uk
akouos
boston blog main
deals
fda
san francisco blog main
abbvie
allergan
alnylam pharmaceuticals
amag pharmaceuticals
amunix
anirvan ghosh
astellas pharmaceuticals
astrazeneca
biogen
bluerock therapeutics
boston
boulder/denver blog main
boulder/denver top stories
california institute for biomedical research
cancer
cancer immunotherapy
cerovene
covid-19
crispr
decibel therapeutics
What
medicines
5
×
plans
5
×
brexit
charting
choppy
course
dynamic
end
period
post
regulation
regulatory
reveals
transition
uk
ipo
acquisitions
affects
americans
announced
approved
bio
ceo
collabs
covid
daniel
date
deal
developing
drug
fda
frequency
gilead
gilead’s
hearing
help
introduce
loss
meds
millions
Language
unset
5
×
Current search:
plans
×
unset
×
medicines
×
@xconomy.com
4 years ago
Bio Roundup: Gilead’s $4.9B Deal, COVID-19 Collabs, IPO Plans & More
@xconomy.com
4 years ago
UK Reveals Plans For ‘Dynamic’ Post-Brexit Regulatory System
@xconomy.com
4 years ago
UK Reveals Plans For ‘Dynamic’ Post-Brexit Regulatory System
@xconomy.com
4 years ago
UK Reveals Plans For ‘Dynamic’ Post-Brexit Regulatory System
@xconomy.com
4 years ago
Frequency Plans IPO for Hearing Loss Drug & More Regenerative Meds